What I find particularly interesting about the result is that Relenza was the third largest drug by revenue for GSK during the quarter, behind Seretide/Advair and Valtrex.
GSK wont be able to ignore the very real importance of Relenza to its profitability and will drive Relenza sales a lot harder. Relenza sales will still be subject to flu seasons and government orders but, no doubt, extra support from GSK will go a long way in both markets.
